Wen Kai Xiang
Directeur/Membre du Conseil chez Immunitas Therapeutics, Inc.
Profil
Wen Kai Xiang is currently a Director at Immunitas Therapeutics, Inc. He previously worked as a Managing Director at Burrill LLC, a Portfolio Manager at Franklin Advisers, Inc., an Associate at The Biotechnology Greenhouse Corp.
of Southeastern PA, and a Vice President-Business Development at Genyous Biomed International, Inc. He also served as a Director at Acacia Research Corp., Gossamer Bio, Inc., Viela Bio, Inc., and Transcenta Holding Ltd.
Prior to his career in business, he worked as a Research Associate at Sinopharm Group Co., Ltd.
Dr. Xiang holds an MBA from the University of Pennsylvania, a doctorate from Stony Brook University, and an undergraduate degree from Fudan University.
Postes actifs de Wen Kai Xiang
| Sociétés | Poste | Début |
|---|---|---|
Immunitas Therapeutics, Inc.
 Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Wen Kai Xiang
| Sociétés | Poste | Fin |
|---|---|---|
Franklin Advisers, Inc.
 Franklin Advisers, Inc. Investment ManagersFinance Franklin Advisers, Inc. is a mutual fund manager and registered investment advisor headquartered in San Mateo, California. The firm was founded in 1985 and is a subsidiary of Franklin Resources, Inc. (NYSE: BEN), a holding company that, together with its various subsidiaries is referred to as Franklin Templeton Investments. Franklin Advisers provides investment advisory and portfolio management services to US and non-US, registered open-end and closed-end funds and unregistered funds, as well as separate accounts. | Analyst-Equity | 31/10/2011 |
Genyous Biomed International, Inc.
 Genyous Biomed International, Inc. Packaged SoftwareTechnology Services Genyous Biomed International, Inc. engages in the discovery, development, and manufacture of multifunctional multi targeted (MFMT) therapies to prevent, detect, and treat cancer and other chronic diseases. The firm offers MFMT therapies, which include anti-viral, anti-oxidative, anti-inflammatory, and immune modulating therapeutic effects for the treatment of solid tumors and related chronic diseases. The company was founded by Jeffrey Dao and James Dao in 2000 and is headquartered in and is headquartered in Henderson, NV. | Corporate Officer/Principal | 31/12/2003 |
The Biotechnology Greenhouse Corp. of Southeastern PA
 The Biotechnology Greenhouse Corp. of Southeastern PA Investment ManagersFinance The Biotechnology Greenhouse Corp. of Southeastern PA (BioAdvance) is a venture capital firm founded in 2002. The firm is headquartered in Philadelphia, Pennsylvania. | Corporate Officer/Principal | - |
| ACACIA RESEARCH CORPORATION | Corporate Officer/Principal | - |
| SINOPHARM GROUP CO. LTD. | Corporate Officer/Principal | 01/07/1992 |
Formation de Wen Kai Xiang
| Fudan University | Undergraduate Degree |
| University of Pennsylvania | Masters Business Admin |
| Stony Brook University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ACACIA RESEARCH CORPORATION | Commercial Services |
| SINOPHARM GROUP CO. LTD. | Distribution Services |
| GOSSAMER BIO, INC. | Health Technology |
| TRANSCENTA HOLDING LIMITED | Health Technology |
| Entreprise privées | 6 |
|---|---|
Franklin Advisers, Inc.
Franklin Advisers, Inc. Investment ManagersFinance Franklin Advisers, Inc. is a mutual fund manager and registered investment advisor headquartered in San Mateo, California. The firm was founded in 1985 and is a subsidiary of Franklin Resources, Inc. (NYSE: BEN), a holding company that, together with its various subsidiaries is referred to as Franklin Templeton Investments. Franklin Advisers provides investment advisory and portfolio management services to US and non-US, registered open-end and closed-end funds and unregistered funds, as well as separate accounts. | Finance |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Finance |
Genyous Biomed International, Inc.
Genyous Biomed International, Inc. Packaged SoftwareTechnology Services Genyous Biomed International, Inc. engages in the discovery, development, and manufacture of multifunctional multi targeted (MFMT) therapies to prevent, detect, and treat cancer and other chronic diseases. The firm offers MFMT therapies, which include anti-viral, anti-oxidative, anti-inflammatory, and immune modulating therapeutic effects for the treatment of solid tumors and related chronic diseases. The company was founded by Jeffrey Dao and James Dao in 2000 and is headquartered in and is headquartered in Henderson, NV. | Technology Services |
The Biotechnology Greenhouse Corp. of Southeastern PA
The Biotechnology Greenhouse Corp. of Southeastern PA Investment ManagersFinance The Biotechnology Greenhouse Corp. of Southeastern PA (BioAdvance) is a venture capital firm founded in 2002. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Health Technology |
